Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Invex Therapeutics Ltd

IXC.AX ✓ COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.07

▲ +0.00%

Market Cap $5.55M · Vol 43.96K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$5.55M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

N/A

YoY

RSI (14)

40.00

Momentum

Beta

0.52

vs Market

52W High

$0.11

27.11% below

52W Low

$0.06

18.22% above

Volume

43.96K

Avg 17.09K

P/B

1.73

Price-to-book

ROE

N/A

Return on equity

Free Float

36.07%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Invex Therapeutics Ltd (IXC.AX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IXC.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.00%

-8.70%

+5.00%

YTD

-12.50%

+0.00%

+116.15%

-43.93%

Financials & Valuation

TTM · Annual

Total Revenue	$121.19K
Net Income	$-935,688.00
Revenue Growth (YoY)	-86.20%
Gross Margin	100.00%
Operating Margin	-781.75%
Net Profit Margin	-772.09%
ROE	N/A
ROA · ROIC	-28.38% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	38.62
P/B	1.73
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	75.15M

Technical Indicators

50-Day SMA	$0.08
200-Day SMA	$0.08
RSI (14)	40.00
Beta	0.52
52-Week High	$0.11
52-Week Low	$0.06

Volume Today	43.96K
Avg Daily Volume (30D)	17.09K
Relative Volume	2.57x
Volatility (10D)	68.01
Volatility (30D)	49.06
Free Float	36.07%

Analyst Consensus

N/A

Current Price $0.07

Mean Target N/A

52W Low$0.06 52W High$0.11

Current

Target

$0.06 $0.11

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00PD615Z5

ISINAU0000048621

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG +0.74% ONC BeOne Medicines AG -1.08% 068270.KS Celltrion, Inc. -1.67% MEDP Medpace Holdings, Inc. -1.29% CRL Charles River Laboratories International, Inc. -1.51%

Company Profile

Invex Therapeutics Ltd is an Australia-based biopharmaceutical company. The Company is focused on the repurposing of an already-approved drug, Exenatide, for the efficacious treatment of neurological conditions derived from or involving raised intracranial pressure (ICP). In addition, the Company has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. The principal activity of the Company is the development of Exenatide, including generating new pre-clinical data in Alzheimer’s Disease (AD) under a collaboration with Tessara Therapeutics. The Company has trademarked its repurposed Exenatide as Presendin. The Company is focused on managing the close out of the Phase III Idiopathic Intracranial Hypertension (IIH) EVOLVE clinical trial and explore new potential applications for Exenatide in TBI and other neurological disorders with raised ICP, consistent with its patents.